In the midst of new emerging therapy projects under development, the progress of innovative manufacturing technologies is also growing. One of the newest emerging platforms for biologics manufacturing is the plant made pharmaceutical platform (PMP). PMP has come on-stage recently with the approval of Canada-based Medicago’s COVID-19 vaccine in Canada, COVIFENZ (plant-based virus-like particles, recombinant, adjuvanted) (1).
The wave of acceptance that has arisen with other platforms, such as baculovirus and messenger RNA, adds to the dominant mammalian cell systems. Plant-made pharmaceuticals will likely be added to the mix, according to Barry Holtz, chief scientific officer, Phylloceuticals.